**ABSTRACT**

The goal of the project is to use the quality-by-design (QbD) method to create and optimise Tofacitinib citrate matrix tablets with controlled release excipients. The drug's physicochemical parameters, reference product characterisation, QTPP (Quality Target Product Profile), and CQAs were used to start product development (Critical Quality Attributes). Hypromellose (Methocel K100 premium LV CR), Polyethylene Oxide (SentryPolyox WSR N80 LEO), and Magnesium Stearate were used as formulation variables and were optimised together. The complete factorial design of experiment (DOE) with three centre points was used to investigate traditional monolithic controlled release matrix tablets. Using Design-expert12 programme, dissolution was assessed as CQA. At acidic pH, hypromellose with a higher viscosity grade provides a regulated release pattern by retaining the integrity of the medication and preventing rapid drug release. Due to the nonionic nature of the polymer, drug release from the polymer matrices is pH independent. Present monolithic controlled release matrix system the extensive degradation of Tofacitinib Citrate in the acidic condition can be avoided with desired in-vitro drug release.

**Keywords:** Quality-by-design; design of experiment; controlled release; dissolution; matrix system.
1. INTRODUCTION

In pharmaceutical research, a novel drug delivery system is presently a demanding technology-based drug delivery system. One of the most ideal platforms for medication design linked to patient safety and efficacy is the controlled release drug delivery system. The medicine is released at a steady pace in a controlled release dose form, allowing therapeutic plasma levels to be maintained. It lowers the frequency of dose and lessens the risk of side effects [1].

The easiest way to construct a dosage form is to use a formulation that contains a hydrophilic matrix polymer. The medication release rate can be maintained at a predetermined pace depending on the viscosity grade of the polymer. When the polymer comes into contact with aqueous solutions, it hydrates and forms a gel layer via diffusion or erosion, resulting in drug release [2].

The present scientific and methodological approach to pharmaceutical development and manufacture is known as Quality by Design. The goal of pharmaceutical development is to obtain the required quality while considering the drug's safety and efficacy [3]. During development, the initial risk assessment determines if the project is high risk, medium risk, or low risk. High risk is unacceptable; further research is required to lower the risk. Medium Risk is tolerable; nevertheless, additional inquiry may be required to lower the risk and improve the situation. Low risk is a danger that can be tolerated by most people; no more inquiry is required. The Quality by Design technique provides a thorough knowledge of the process parameters and material properties that have an influence on the pharma product's critical quality attributes (CQA), safety, and efficacy during its development. The Quality by Design (QbD) method creates a stable formulation and manufacturing process, as well as an appropriate control system, to assure the drug's performance. Design of Experiments aids in the creation of the Design space for Formulation, as well as the evaluation of process factors and desired responses using design expert software version 12 [4,5,6,7].

The current study focuses on Tofacitinib citrate controlled release tablets, an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis that is recommended for the treatment of moderately to severely active rheumatoid arthritis (RA). JAK enzymes pair to transmit cytokine signalling (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Many proinflammatory cytokines (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2) signal through common-chain-containing receptors, which is suppressed by the JAK pathway. Tofacitinib citrate has a quick absorption and elimination profile, with a time to maximum plasma concentration (Tmax) of 0.5-1 hour and a terminal half-life (t1/2) of 3-4.5 hours [8,9,10].

Tofacitinib citrate is classified as a BCS Class III medication (low permeability, high soluble) [11]. In a saturation solubility investigation, drug ingredient solubility was found to be pH dependant. The highest solubility was found in 0.1N hydrochloric acid, and solubility diminishes as pH rises. Tofacitinib citrate tablets with controlled release formulations were created employing the release regulating polymer Polyethylene oxide, Hypromellose (Methocel K100 premium LV CR) in the core tablets and Ethyl cellulose, Hydroxy propyl cellulose (Klucel LF) in the coating composition and drug release throughout the gastrointestinal tract [12,13,14].

2. MATERIALS AND METHODS

2.1 Materials

Tofacitinib citrate was gifted from Aurobindo Pharma Limited, India., Microcrystalline cellulose was gifted from Crest cellulose Private Ltd., Hypromellose and Ethyl cellulose was gifted from Coloron asia pacific Pvt. Ltd. Polyethylene oxide was gifted from Dow chemical company. Hydroxypropyl cellulose was gifted from Ashland, Butylated hydroxytoluene was gifted from Merck, Colloidal silicon dioxide was gifted from Evonik Industries, magnesium stearate was gifted from crest cellulose private Ltd.

2.2 Manufacturing Method

The present study design focus on conventional monolithic controlled release matrix tablets with Polyethylene oxide, Hypromellose (Methocel K100 premium LV CR) in core tablets and Ethyl cellulose, Hydroxy propyl cellulose (Klucel LF) in coating composition. The formulation was manufactured with wet granulation technique with high shear rapid mixture granulator and non-aqueous solvent was used as granulating fluid.

2.3 Method of Analysis

Drug product method of analysis not available in USP monograph. Hence, dissolution method was adopted in following in-house developed method.
2.4 Dissolution Method

**Buffer Solution Preparation:** Dissolve 68 g of potassium dihydrogen orthophosphate and 8.9 g of sodium hydroxide pellets in 10 liters of water and mix well. pH maintains at 6.8±0.05 with 0.2N sodium hydroxide.

Mobile phase buffer preparation: Add 1 ml of trifluoro acetic acid into 1000 ml of milliq water.

**Mobile Phase Preparation:** Mix the buffer with acetonitrile in the ratio of 80:20v/v.

Instrumentation: A high performance liquid chromatographic system with waters 2695 separation module used for analysis.

Chromatographic conditions for HPLC:

| Column                  | Kromasil 100-5 C18 (150 mm x 4.6 mm), 5µ |
|-------------------------|------------------------------------------|
| Pump mode               | Isocratic                                |
| Flow rate               | 1.0 mL/minute                             |
| Detection              | UV, 292 nm                                |
| Injection               | 60 µL                                     |
| Columnoven temperature  | 40°C                                      |
| Run time               | 10 minutes                                |

2.5 Assay Method

Chromatographic conditions: The HPLC is equipped with a Kromasil 100-5 C18 (150 mm x 4.6 mm), 5µ column, Isocratic pump mode, 1.0 mL/minute flow rate, UV, 292 nm detection, injection volume-60 µL, Temperature-35°C, Run time-15 minutes.

3. EXPERIMENTAL DESIGN

Preformulation studies aid in the knowledge of the drug substance’s physico-chemical properties such as solubility, stability, compatibility, and solid-state characteristics, which are followed by drug excipient compatibility studies. Differential scanning calorimetry and physical examination were used to assess the tofacitinib drug substance and appropriate excipients at various concentrations.

3.1 Tofacitinib Citrate Drug Ingredient Hygroscopicity Studies

Tofacitinib medicinal material was studied for hygroscopicity by exposing it to an 80 percent RH environment for 24 hours and calculating the percent mass change. Table 1 summarises the findings. The maximum weight gain in the hygroscopicity testing was 0.102 percent at 80 percent RH based on three samples. As a result, a weight increase of less than 2% suggests that the Tofacitinib product is non-hygroscopic.

**Solubility Study of Tofacitinib Citrate:** Saturation solubility of Tofacitinib citrate drug substance was carried out in the pH range of 1.2 to 7.5 and the results are tabulated below Table 2.

| Solvent              | pH observed after addition of drug (after 24 Hr.) | Solubility (mg/ml) | Dose/Solubility ratio(mL)* |
|----------------------|---------------------------------------------------|--------------------|---------------------------|
| 0.1N Hcl             | 1.02                                              | 7.013              | 1.426                     |
| pH 4.5 Acetate Buffer| 4.43                                              | 0.910              | 11.099                    |
| Purified water       | 5.75                                              | 2.732              | 3.660                     |
| pH 6.8 Phosphate Buffer| 6.65                                              | 0.225              | 44.44                     |
| pH 4.5 Phosphate Buffer| 7.35                                              | 0.144              | 69.44                     |

*Dose/Solubility = $\frac{\text{Highest Dose[mg]}}{\text{Saturation Concentration[mg/ml]}} \leq 250$ mL
Solid State Characterization: Tofacitinib citrate drug substance used in the present study exhibits crystalline form. Tofacitinib citrate drug substance have been analyzed by X-Ray powder diffraction the 2-Theta value presented in Table 3. The diffractogram presented in Fig. 1.

3.2 Formulation Design Experiments

Quality by Design (QbD): Designing for quality requires a scientific foundation. Pharmaceutical development starts with a purpose in mind, which helps to clarify product and process quality. The quality goal product profile, the critical quality characteristic, the critical process parameters, and the control plan are all included. According to the current research, the amount of hydrophilic polymer in core tablets and the amount of pore-forming hydrophobic polymer has a direct effect on the important quality characteristic.

Early in the development process, the aim is established based on the qualities of the drug ingredient. The outcome of creating a formulation and manufacturing process with an appropriate control plan that assures medication performance from start to end. Physical and chemical properties that are within a certain limit or range, allowing it to fit into the design space. From the QTPP the CQA was identified based on risk assessment those are outside the acceptable range for that attribute.

| S. No. | 1   | 2   | 3   | 4   | 5   | 6   | 7   |
|-------|-----|-----|-----|-----|-----|-----|-----|
| 2-Theta value | 5.84 | 14.91 | 16.10 | 16.28 | 20.35 | 21.18 | 27.05 |

Fig. 1. XRD data of Tofacitinib drug substance

Table 3. Theta value of crystalline form of Tofacitinib citrate

Table 4. Quality target product profile (QTPP)

| Identification of QTPP | Target |
|-----------------------|--------|
| Dosage form           | Oral Tablets |
| Dosage design         | Monolithic controlled release dosage form |
| Administration route  | Oral |
| Stability             | Ensure impurity levels as per ICH and stable polymorphism |
| Physical attributes   | To maintain as per quality standard |
| Identification        | Should be consistent prior to development |
| Dissolution           | Percentage drug release as per specific requirements. |
| Degradation Product   | Specified and unspecified impurity should be within limits |
| Polymorphism          | Should be consistent during manufacturing process and storage |
| Differential scanning calorimetry (DSC) | Should be consistent during manufacturing process and storage |
Table 5. Critical quality attributes (CQA)

| Quality attributes of Drug product | Target | Critical/Noncritical | Justification |
|-----------------------------------|--------|----------------------|---------------|
| Appearance                        | Color, size and shape | Noncritical         | It can’t be correlate Tablet Color, size and shape to patient safety |
| Odor                              | Odor of tablet       | Noncritical         | As the drug and excipients does not have odor. It can’t be correlate Tablet odor to patient safety |
| Size                              | Easy to Swallow      | Noncritical         | Smaller size of the tablets designed for patient compliance and acceptance. |
| Physical attributes               | Friability           | Noncritical         | It is not directly link to patient safety. It gives strengths to quality of product. |
|                                   | Hardness             | Critical            | Compression force and formulation components impact hardness. |
| Identification                    | Original form of Drug substance | Critical         | Formulation and process variability may unlikely impact on Identity. |
| Related substance                 | Any unspecified Impurity: NMT 0.2%/w/w Total Impurity: NMT 1.0%/w/w | Critical | Input materials of drug substance, excipients and process parameters impacts degradation product. |
| Assay                             | 95%-105%            | Critical            | Input materials of drug substance, excipients and process parameters impacts assay of product. |
| Dissolution                       | 2 Hrs- 25-35% 4 hrs- 40-60% 6 Hrs-60-75% 8 Hrs - NLT 80 % | Critical | Input materials of drug substance, excipients and Process parameters impacts assay of product. |
| Polymorphism                      | Consistent throughout development | Critical | Polymorphism should be retained during manufacturing process and storage. |

At the initial stage of QbD development, material attributes that impact the quality of the product was identified through risk assessment process and categorized the risk. Based on the risk analysis formulation factors are evaluated through experiments to understand the resultant response through design of experiment process.

Formulation factor impacted the quality are:

- Input material of drug product and selected excipients.
- Critical process parameters for Manufacturing process.
- Control strategy with range and limits.

Initial Risk Assessment of Formulation Variables Impact on Drug Product CQA: An initial risk assessment was evaluated based on the prior knowledge of drug substance and the excipients used in the manufacturing of dosage form and that formulation variable have high risk on affecting drug product CQA. The results of initial risk assessment are represented in below table and the justification of the risk prioritization is presented. Each formulation variable that has a high risk to impact the drug product CQAs is further evaluated in subsequent risk assessments to determine which formulation variables need to be studied to reduce the risk.
Table 6. Initial risk assessment of formulation variables

| Drug product CQAs | Formulation Variables | Microcrystalline Cellulose Level | Hypromellose Level | Polyethylene Oxide Level |
|-------------------|------------------------|----------------------------------|--------------------|--------------------------|
| Assay             | Low                    | Low                              | Low                |
| Dissolution       | Low                    | High                             | High               |
| Related substance | Low                    | Low                              | Low                |

Table 7. Justification for the initial risk assessment of formulation variables

| Formulation Variables | Drug product CQAs | Justification |
|-----------------------|-------------------|---------------|
| Microcrystalline Cellulose Level | Assay | Microcrystalline Cellulose is used as diluent/filler. It improves the flow property of the blend. Hence it will not impact the assay of finish product. So, the risk is low. |
|                       | Dissolution       | Microcrystalline Cellulose is used as diluent/filler. It improves the flow property of the blend. Hence it will not impact the dissolution of finish product. So, the risk is low. |
|                       | Related substance | Microcrystalline Cellulose is used as diluent/filler in intragranular stage. It improves the flow property of the blend and improves the bulk density of the blend. Hence it will not impact the Related substance of finish product. So, the risk is low. |
| Hypermellose (Methocel K100 premium LV CR) Level | Assay | Hypermellose (Methocel K100 premium LV CR) is used as release retardant hydrophilic polymer. It has good binding properties. Hence it will not impact the assay of finish product. So, the risk is low. |
|                       | Dissolution       | Hypermellose (Methocel K100 premium LV CR) is used as release retardant hydrophilic polymer. It has good binding properties. Hence it will impact the dissolution of finish product. So, the risk is High. |
|                       | Related substance | Hypermellose (Methocel K100 premium LV CR) is used as release retardant hydrophilic polymer. It has good binding properties. During drying process required amount of moisture was kept to avoid gelling and swelling nature of the blend. Hence it will not impact the Related substance of finish product. So, the risk is Low. |
| Polyethylene Oxide (sentryPolyox WSR N80 LEO) Level | Assay | Polyethylene Oxide (sentryPolyox WSR N80 LEO) is used as release retardant hydrophilic polymer. It has good binding properties. Hence it will not impact the assay of finish product. So, the risk is low. |
|                       | Dissolution       | Polyethylene Oxide (sentryPolyox WSR N80 LEO) is used as release retardant hydrophilic polymer. It has good
| Formulation Variables | Drug product CQAs | Justification |
|-----------------------|-----------------|---------------|
| Related substance     | Drug product binding properties. Hence it will impact the dissolution of finish product. So, the risk is High. | Polyethylene Oxide (sentryPolyox WSR N80 LEO) is used as release retardant hydrophilic polymer. It under go oxidation properties. So, Butylated Hydroxy Toluene added in formulation as antioxidant. During drying process required amount of moisture was kept to avoid gelling and swelling nature of the blend. Hence it will impact the related substance of finish product. So, the risk is low. |
| Magnesium stearate    | Assay           | Magnesium stearate is used as lubricant. Hence, it will impact the assay of finish product. So, the risk is low. | Magnesium stearate is used as lubricant. It has the higher surface area and lipophilic in nature. Hence, it may impact the dissolution of finish product. So, the risk is medium. |
| Colloidal silicon dioxide Level | Assay | Colloidal silicon dioxide is used as glidant. Colloidal silicon dioxide has smaller particles and larger surface area which improves the flow property of the blend. It is used as adsorbent which adsorb the surface moisture from the blend and tablets. Hence it will not impact the assay of finish product. So, the risk is low. | Colloidal silicon dioxide is insoluble in water. It doesn’t have any binding properties. Hence it will not impact the dissolution of finish product. So, the risk is low. |
| Butylated Hydroxy Toluene Level | Assay | Butylated Hydroxy Toluene is used as an antioxidant and prevents oxidation during storage. It is unlikely impact the assay. Hence the risk is Low. | Butylated Hydroxy Toluene is not release controlling polymer. It is unlikely impact the dissolution. Hence the risk is Low. |

**Formulation and Development:** Based on literature data and a preformulation research, tofacitinib citrate Tablets were developed as a controlled release drug delivery system. Controlled release hydrophilic excipients were chosen depending on the release characteristics of the target medication. Tofacinib citrate drug substance and Hypromellose (Methocel K100 premium LV CR) were processed together with an ASTM 30 mesh sieve (600 micron screen). The remaining intra-granular material, such as Microcrystalline Cellulose (Avicel PH 101), Polyethylene Oxide (sentryPolyox WSR N80 LEO), and Colloidal Silicon Dioxide, was sorted using an ASTM 25 mesh screen (710-micron screen). For consistent mix homogeneity, all sifted ingredients are passed through an ASTM 25 mesh (710-micron screen). For the manufacture of granulating fluid, butylated hydroxy toluene was dissolved in isopropyl alcohol. Over the course of three minutes, the dry mix blend was granulated with the non-aqueous granulating fluid in a high shear mixer granulator with impeller slow and chopper slow speeds. Using an IR moisture analyser, the wet mass was dried in a Fluid bed processor at inlet temperature 45°C-5°C for 1 hour to achieve the target moisture content value of less than 3%.
w/w. Through a 0.8mm screen, the dry granules were co milled. Extragranular Microcrystalline Cellulose (Avicel PH 102) was blended with dried granules in a low shear cone blender for 10 minutes after passing through an ASTM 40mesh (425-micron screen). Magnesium Stearate was screened using an ASTM 60 mesh (250 micron screen) before being mixed with the aforesaid mixture and lubricated for 3 minutes. With the use of appropriate punches, the lubricated mix was crushed into a tablet. To avoid dosage dumping, a functional coating dispersion was made by dissolving ethylcellulose (Ethocel 4 cP STD. Primium) and hydroxypropyl cellulose (Klucel-LF) in a hydroalcoholic solvent with Triethyl Citrate as a plasticizer and Talc as an anti-adherent. The aforesaid functional coating dispersion was applied to the core tablets. Table 8 shows the unit composition of the formulation trails. The prototype formulation was created first, followed by a design of experiment (DoE) using the specified component, and the response was analysed in Table 8.

Table 8. Unit composition of prototype controlled release formulation

| Ingredients                                      | Quantity per unit (mg) |
|--------------------------------------------------|------------------------|
| Tofacitinib Citrate*¥                             |                        |
| Microcrystalline Cellulose (Avicel PH 101)#      |                        |
| Hypromellose (Methocel K100 premium LV CR)       |                        |
| Polyethylene Oxide(sentryPolyox WSR N80 LEO)     |                        |
| Colloidal silicon dioxide                        |                        |
| Butylated Hydroxy Toluene                        |                        |
| Isopropyl Alcohol                                |                        |
| Extragranular                                    |                        |
| Microcrystalline Cellulose (Avicel PH 102)       |                        |
| Magnesium Stearate                               |                        |
| Core Tablet Weight                               |                        |
| Functional Coating                               |                        |
| Ethylcellulose (Ethocel 4 cP STD. Primium)       |                        |
| Hydroxypropyl cellulose (Klucel-LF)              |                        |
| Triethyl Citrate                                 |                        |
| Talc                                             |                        |
| Isopropyl alcohol                                |                        |
| Purified Water                                   |                        |
| Total Weight                                     |                        |

* Tofacitinib 11 mg (equivalent to Tofacitinib citrate 17.77 mg)
¥ This quantity is based on 100% w/w assay (on anhydrous basis and solvent free basis) and nil water content
Quantity (mg/Tab) = Label Claim \times \frac{100}{\text{% w/w assay (on anhydrous basis and solvent free basis)}} \times \frac{100}{\text{100-(% w/w water content + % w/w solvent content)}}

**Physical Characteristic of Lubricated Blend Parameters:** The flow qualities of the mix are determined by the physical characteristics of the blend. Bulk density (gm/ml) is calculated as the weight of the blend divided by the volume of the mix. A 100ml measuring cylinder with originally weighted blend samples was progressively emptied into a 10mm cylinder and stored in a densitometer to estimate its density (gm/ml) (electro lab Tapped density apparatus). The initial volume of the lubricated mix was recorded, and the ultimate volume was calculated by tapping the cylinder 500 times. Continue punching in for a total of 750 times, taking note of the final volume. I tapped the cylinder 1250 times and recorded the volume [15].

TD= Initial weight (gm)/ Tapped final volume (ml)

Hauser’s Ratio was determined by using following formula,

\[ HR = \frac{\text{Tapped density (m/v)}}{\text{Bulk density (m/v) \times 100}} \]

% Carr’s index was determined by using following formula,

\[ % \text{ CI}= \frac{\text{Tapped density (m/v)- Bulk density(m/v)}}{\text{Tapped density(m/v) \times 100}} \]

Angle of repose was determined by using following formula,

\[ \tan \theta = \frac{\text{Cone height}}{\text{Heap radius}} \]

Tofacitinib citrate lubricated blend was pass through a funnel with a maximum height level which is placed vertically and measured the maximum possible angle between the cone height (h) of powder blend and the heap radius (r).

**Compression of Tofacitinib Citrate Lubricated Blend:** Eliza Press compression machine with 6x3mm capsule form punches was used to compress the tablets. The ideal hardness range and machine speed were used to compress the tablet. The prototype formulation mix was compressed and tested in its entirety. The tablets were examined for physical defects such as sticking, picking, capping, cracking, and other undesirable qualities. Twenty pills were chosen at random, and the uniformity weight and average weight of the tablets were recorded.

Digital vernier callipers were used to measure the thickness (mm) and hardness (KP) of 20 tablets from each batch. The initial weight of 10 pills was recorded, and they were then placed in a Roche friabilator and spun for 100 revolutions at 25 rpm before being de-dusted and reweighed. The following formula was used to compute the % friability:

\[ \text{Percentage friability} (\%) = \left( \frac{A1-B1}{B1} \right) \times 100 \]

where, \( A1 \) = Initial weight of tablets, \( B1 \) = Final weight of tablets after 100 revolutions

Table 9. Physical characterization data of lubricated blend

| Batch No: | F1  | F2  | F3  | F4  | F5  | F6  | F7  | F8  | F9  |
|-----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Bulk density(gm/ml) | 0.624 | 0.612 | 0.621 | 0.615 | 0.627 | 0.623 | 0.624 | 0.614 | 0.624 |
| Tapped density(gm/ml) | 0.765 | 0.761 | 0.753 | 0.768 | 0.761 | 0.762 | 0.766 | 0.759 | 0.758 |
| Compressibility Index(%) | 18.43 | 19.58 | 17.53 | 19.92 | 17.60 | 18.24 | 18.53 | 19.10 | 17.67 |
| Hausner’s ratio | 1.226 | 1.243 | 1.213 | 1.249 | 1.214 | 1.223 | 1.228 | 1.236 | 1.215 |

Table 10. Physical properties of compressed tablets data

| Core Tablets parameters/B.No: | F1  | F2  | F3  | F4  | F5  | F6  | F7  | F8  | F9  |
|-------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Average weight(mg)           | 162 | 163 | 162 | 162 | 163 | 161 | 162 | 162 | 161 |
| Uniformity                   | 158- | 160- | 161- | 160- | 161- | 160- | 163- | 161- | 160- |
| weight(mg), min-Max          | 165 | 164 | 167 | 164 | 168 | 165 | 167 | 165 | 167 |
| Hardness(kp), Min            | 6.2- | 6.5- | 6.7- | 7.2- | 6.7- | 6.1- | 6.4- | 7.3- | 6.9- |
Table 11. Physical properties of coated tablets data

| Coated Tablets parameters/B.No: | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 |
|---------------------------------|----|----|----|----|----|----|----|----|----|
| Max thickness (mm), Min-Max     | 3.75-3.84 | 3.74-3.85 | 3.73-3.86 | 3.75-3.87 | 3.75-3.86 | 3.75-3.87 | 3.75-3.86 | 3.75-3.87 | 3.75-3.86 |
| Friability (%)                  | 0.06 | 0.03 | 0.02 | 0.01 | 0.02 | 0.03 | 0.07 | 0.05 |

Based on the initial risk assessment and the preliminary feasibility study, a design of experiment with full factorial design was performed for Tofacitinib citrate tablets formulation. Drug release profile in Phosphate Buffer, pH 6.8 at time intervals 2 hours, 4 hours, 6 hours and 8 hours were identified as CQA of the formulation F7 composition.

4. RESULTS AND DISCUSSION

4.1 Drug Dissolution and Defining Design Space

Dissolution of Prototype evaluated from F1 to F9. Based on the initial risk assessment and the preliminary feasibility study, a design of experiment with full factorial design was performed for Tofacitinib citrate tablets formulation. Drug release profile in Phosphate Buffer, pH 6.8 at time interval 2 hours, 4 hours, 6 hours and 8 hours were identified as a CQA of the formulation F7 composition.

4.2 Optimization of Hypromellose (Methocel K100 Premium LV CR), Polyethylene Oxide (sentryPolyox WSR N80 LEO) and Magnesium Stearate Levels in mg

Based on the initial risk assessment, full factorial design of experiment (DOE) with three center points was studied and from the results of the formulation trails using Design- expert 12 software was performed to optimize Hypromellose (Methocel K100 premium LV CR), Polyethylene Oxide (sentryPolyox WSR N80 LEO) and Magnesium Stearate in combination as formulation variables. Drug release at different time points was considered as response. This study also sought to establish the robustness of the proposed formulation.

Swelling index of Tofacitinib Citrate Controlled Release Tablets: Swelling index of Tofacitinib citrate controlled release Tablets was determined at temperature 37 ± 0.5°C in pH 4.5 Phosphate buffer over a period of 12 hours. One tablet from each formulation was kept in a petri dish containing 50 ml of buffer solution. Weight of individual tablets was taken initially for swelling study (M1). Aliquot was discarded form the petri dish after 12 hours then blot the swelled tablets in tissue paper and recorded the final weight (M2) and final weight of the tablets taken after 12 hours(M2). Swelling index was calculated using following formula,

Swelling index = (M2 - M1) x 100/M2,

Where M1 is the initial weight of tablet and M2 is the weight of hydrated tablet [16].

Coating of Tofacitinib Citrate Controlled Release Tablets: Tablets were coated by using Ganson coating machine 6" coating pan. The physical properties of the tablets like hardness, thickness, were evaluated. All coating machine parameters like spray rate, atomization air pressure, inlet temperature, bed temperature, exhaust temperature, pan speed was evaluated. Coated Tablets physical properties were represented in Table 11.

Dissolution Study: Dissolution study of tofacitinib citrate controlled release tablets was performed by using USP type-II (Paddle) apparatus, Phosphate Buffer, pH 6.8 as dissolution medium at 50 rpm, volume 900ml. The apparatus was maintained temperature at 37°C ± 0.5°C. At the regular time of intervals (2,4,6 and 8hours) samples was withdrawn and replaced with fresh Phosphate Buffer, pH 6.8 media. Cumulative % drug release was analyzed by HPLC.
Table 12. 2^3 factorial design to study Hypromellose (Methocel K100 premium LV CR), polyethylene Oxide (sentry Polyox WSR N80 LEO) and magnesium stearate levels in combination

| Factors: Formulation variables | Levels (%) |
|--------------------------------|------------|
| A: Hypromellose (Methocel K100 premium LV CR) | 14.00 17.50 21.00 |
| B: Polyethylene Oxide (sentry Polyox WSR N80 LEO) | 8.00 10.00 12.00 |
| C: Magnesium Stearate | 1.00 1.50 2.00 |

Responses

| Responses | Goal | Acceptance Ranges |
|-----------|------|-------------------|
| Y1: Dissolution at 2Hrs | Range | Between 25-35% |
| Y2: Dissolution at 4Hrs | Range | Between 40-60% |
| Y3: Dissolution at 6Hrs | Range | Between 60-75% |
| Y4: Dissolution at 8Hrs | Range | Not Less Than 80% |

Table 13. Formulation variables and response in different time interval

| Factor 1 | Factor 2 | Factor 3 | Response 1 | Response 2 | Response 3 | Response 4 |
|----------|----------|----------|------------|------------|------------|------------|
| A: Hypromellose | B: Polyethylene Oxide | C: Magnesium Stearate | Dissolution in 2 Hours | Dissolution in 4 Hours | Dissolution in 6 Hours | Dissolution in 8 Hours |
| 21 | 12 | 1 | 31 | 43 | 63 | 93 |
| 21 | 12 | 2 | 27 | 40 | 62 | 88 |
| 21 | 8 | 1 | 32 | 52 | 63 | 98 |
| 14 | 8 | 2 | 31 | 44 | 61 | 97 |
| 14 | 12 | 1 | 34 | 45 | 74 | 96 |
| 17.5 | 10 | 1.5 | 33 | 51 | 68 | 97 |
| 17.5 | 10 | 1.5 | 34 | 53 | 67 | 97 |
| 14 | 8 | 1 | 35 | 60 | 75 | 98 |
| 14 | 12 | 2 | 33 | 55 | 71 | 95 |
| 21 | 8 | 2 | 31 | 54 | 67 | 93 |
| 17.5 | 10 | 1.5 | 34 | 52 | 69 | 96 |

ANOVA for Selected Factorial Model: Response 1: Dissolution in 2 Hours.

Table 14. Statistical evaluation of formulation variables and response 1

| Source | Sum of Squares | df | Mean Square | F-value | p-value | Remark |
|--------|---------------|----|-------------|---------|---------|--------|
| Model  | 41.5          | 5  | 8.3         | 49.8    | 0.0011  | significant |
| A-Hypromellose (Methocel K100 premium LV CR) | 18 | 1 | 18 | 108 | 0.0005 | -- |
| B-Polyethylene Oxide (sentry Polyox WSR N80 LEO) | 2 | 1 | 2 | 12 | 0.0257 | -- |
| C-Magnesium Stearate | 12.5 | 1 | 12.5 | 75 | 0.001 | -- |
| AB | 4.5 | 1 | 4.5 | 27 | 0.0065 | -- |
| ABC | 4.5 | 1 | 4.5 | 27 | 0.0065 | -- |
| Curvature | 8.02 | 1 | 8.02 | 48.09 | 0.0023 | -- |
| Residual | 0.6667 | 4 | 0.1667 | -- | -- | -- |
| Lack of Fit | 0 | 2 | 0 | 0 | 1 | not significant |
| Pure Error | 0.6667 | 2 | 0.3333 | -- | -- | -- |
| Cor Total | 50.18 | 10 | -- | -- | -- | -- |
The Model F-value of 49.80 implies the model is significant. There is only a 0.11% chance that an F-value this large could occur due to noise. P-values less than 0.0500 indicate model terms are significant. In this case A, B, C, AB, ABC are significant model terms. Values greater than 0.1000 indicate the model terms are not significant. The Lack of Fit F-value of 0.00 implies the Lack of Fit is not significant relative to the pure error. There is a 100.00% chance that a Lack of Fit F-value this large could occur due to noise. Non-significant lack of fit is good.

**ANOVA for Selected Factorial Model:**
Response 2: Dissolution in 4 Hours.

### Table 15. Statistical evaluation of Formulation variables and response 2

| Source                        | Sum of Squares | df  | Mean Square | F-value | p-value | Remark       |
|-------------------------------|----------------|-----|-------------|---------|---------|--------------|
| Model                         | 345.75         | 6   | 57.63       | 33.73   | 0.0076  | significant  |
| A-Hypromellose (Methocel K100 premium LV CR) | 28.13 | 1  | 28.13       | 16.46   | 0.027   | --           |
| B-Polyethylene Oxide (sentryPolyox WSR N80 LEO) | 91.13 | 1  | 91.13       | 53.34   | 0.0053  | --           |
| C-Magnesium Stearate         | 6.13           | 1   | 6.13        | 3.59    | 0.1546  | --           |
| AB                            | 45.12          | 1   | 45.12       | 26.41   | 0.0143  | --           |
| BC                            | 55.13          | 1   | 55.13       | 32.27   | 0.0108  | --           |
| ABC                           | 120.13         | 1   | 120.13      | 70.32   | 0.0036  | --           |
| Curvature                     | 18.03          | 1   | 18.03       | 10.56   | 0.0475  | --           |
| **Residual**                  | **5.13**       | **3** | **1.71**   | --      | --      | --           |
| Lack of Fit                   | 3.13           | 1   | 3.13        | 3.13    | 0.2191  | not significant |
| Pure Error                    | 2              | 2   | 1           | --      | --      | --           |
The Model F-value of 33.73 implies the model is significant. There is only a 0.76% chance that an F-value this large could occur due to noise. P-values less than 0.0500 indicate model terms are significant. In this case A, B, AB, BC, ABC are significant model terms. Values greater than 0.1000 indicate the model terms are not significant. The Lack of Fit F-value of 3.13 implies the Lack of Fit is not significant relative to the pure error. There is a 21.91% chance that a Lack of Fit F-value this large could occur due to noise. Non-significant lack of fit is good.

**ANOVA for Selected Factorial Model:**
Response 3: Dissolution in 6 Hours.

**Table 16. Statistical evaluation of formulation variables and response 3**

| Source             | Sum of Squares | df | Mean Square | F-value | p-value | Remark       |
|--------------------|----------------|----|-------------|---------|---------|--------------|
| Model              | 222            | 7  | 31.71       | 31.71   | 0.0309  | significant  |
| A-Hypromellose     | 84.5           | 1  | 84.5        | 84.5    | 0.0116  | --           |
| B-Polyethylene     | 2              | 1  | 2           | 2       | 0.2929  | --           |
| Oxide(sentryPolyox|                |    |             |         |         |              |
| WSR N80 LEO)       |                |    |             |         |         |              |
| C-Magnesium        | 24.5           | 1  | 24.5        | 24.5    | 0.0385  | --           |
| Stearate           | 24.5           | 1  | 24.5        | 24.5    | 0.0385  | --           |
| AB                 | 50             | 1  | 50          | 50      | 0.0194  | --           |
| AC                 | 4.5            | 1  | 4.5         | 4.5     | 0.1679  | --           |
| BC                 | 32             | 1  | 32          | 32      | 0.0299  | --           |
| ABC                | 2.18           | 1  | 2.18        | 2.18    | 0.2777  | not          |
| Curvature          |                |    |             |         |         | significant  |
| Pure Error         | 2              | 2  | 1           | --      | --      | --           |
| Cor Total          | 226.18         | 10 | --          | --      | --      | --           |
The Model F-value of 31.71 implies the model is significant. There is only a 3.09% chance that an F-value this large could occur due to noise. P-values less than 0.0500 indicate model terms are significant. In this case A, C, AB, AC, ABC is significant model terms. Values greater than 0.1000 indicate the model terms are not significant.

**ANOVA for Selected Factorial Model:**
Response 4: Dissolution in 8 Hours.

Table 17. Statistical evaluation of formulation variables and response 4

| Source                    | Sum of Squares | df | Mean Square | F-value | p-value | Remark     |
|---------------------------|----------------|----|-------------|---------|---------|------------|
| Model                     | 79.5           | 6  | 13.25       | 59.63   | 0.0033  | significant |
| A-Hypromellose (Methocel K100 premium LV CR) | 24.5       | 1  | 24.5        | 110.25  | 0.0018  | --         |
| B-Polyethylene Oxide (sentryPolyox WSR N80 LEO) | 24.5       | 1  | 24.5        | 110.25  | 0.0018  | --         |
| C-Magnesium Stearate     | 18             | 1  | 18          | 81      | 0.0029  | --         |
| AB                        | 4.5            | 1  | 4.5         | 20.25   | 0.0205  | --         |
| AC                        | 8              | 1  | 8           | 36      | 0.0093  | --         |
| ABC                       | 0              | 1  | 0           | 0       | 1       | --         |
| Curvature                 | 8.02           | 1  | 8.02        | 36.07   | 0.0092  | --         |
| Residual                  | 0.6667         | 3  | 0.2222      | --      | --      | --         |
| Lack of Fit               | 0              | 1  | 0           | 0       | 1       | not significant |
| Pure Error                | 0.6667         | 2  | 0.3333      | --      | --      | --         |
The Model F-value of 59.63 implies the model is significant. There is only a 0.33% chance that an F-value this large could occur due to noise. P-values less than 0.0500 indicate model terms are significant. In this case A, B, C, AB, AC is significant model terms. Values greater than 0.1000 indicate the model terms are not significant. The Lack of Fit F-value of 0.00 implies the Lack of Fit is not significant relative to the pure error. There is a 100.00% chance that a Lack of Fit F-value this large could occur due to noise. Non-significant lack of fit is good. We want the model to fit.

Updated Risk Assessment of Formulation Variables Impact on Drug Product CQA: The results of updated risk assessment are represented in below table and the justification of the risk prioritization is presented.

Table 18. Updated risk assessment of formulation variables

| Drug product CQAs | Formulation Variables |
|-------------------|-----------------------|
|                   | Microcrystalline Cellulose Level | Hypromellose Level | Polyethylene Oxide Level |
| Assay             | Low                    | Low                | Low                     |
| Dissolution       | Low                    | Low*               | Low*                    |
| Related substance | Low                    | Low                | Low                     |
### Table 19. Justification for the initial risk assessment of formulation variables

| Formulation Variables | Drug product CQAs | Justification |
|-----------------------|-------------------|---------------|
| Hypromellose (Methocel K100 premium LV CR) Level | Dissolution | The level of Hypromellose (Methocel K100 premium LV CR) in formulation at the range 14-21mg gives desired dissolution in predetermined rate. In this range study of hydrophilic polymer does not impact the product CQA. The risk is reduced from high to low. |
| Polyethylene Oxide (sentryPolyox WSR N80 LEO) Level | Dissolution | The level of Polyethylene Oxide (sentry Polyox WSR N80 LEO) in formulation at the range 8mg to 12mg gives desired dissolution in predetermined rate. In this range study of hydrophilic polymer does not impact the product CQA. The risk is reduced from high to low. |
| Magnesium stearate | Dissolution | The level of Magnesium stearate in formulation at the range 1mg to 2mg gives desired dissolution in predetermined rate. In this range study of hydrophobic lubricant does not impact the product CQA. The risk is reduced from high to low. |

**Summary of Excipients Range Study of Formulation Variables and Design Space:**
Selected formulation variable clearly indicate that observed drug release was within the selected range. Hypromellose (Methocel K100 premium LV CR) level from 14mg to 21mg, Polyethylene Oxide (sentryPolyox WSR N80 LEO) level from 8mg to 12mg and Magnesium Stearate 1mg to 2mg have entire design space showing drug release between 25-35% in 2 hours, Between 40-60% in 4 hours, Between 60-75% in 6 hours and not less than 80% in 8 hours.

**5. CONCLUSION**

Quality by Design approach gives clear understanding on process parameters and material attributes which impacts on critical quality attributes (CQA), safety and efficacy of the drug product during its lifecycle. Quality by Design (QbD) approach developed a robust formulation and manufacturing process with an acceptable control strategy by Hypromellose (Methocel K100 premium LV CR), Polyethylene Oxide (Sentry Polyox WSR N80 LEO) and Magnesium Stearate was done in combination as formulation variables. Drug release profile in Phosphate Buffer, pH 6.8 at time interval 2 hours, 4 hours, 6 hours and 8 hours.

**DISCLAIMER**

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

**CONSENT**

It is not applicable.

**ETHICAL APPROVAL**

It is not applicable.

**COMPETING INTERESTS**

Authors have declared that no competing interests exist.
REFERENCES

1. Nair AK, Ramana PV, Rao PVB, Reddy BH, Ganthi HKR, Mallu UR. Carobomer Based Controlled Release Designs of Atorvastatin Calcium Tablets Evaluated Using Quality by Design (QbD) Approach, American Journal of Analytical Chemistry. 2017;8:189-209.

2. Mamatha T, et al., Formulation and evaluation of extended release tablets of an antidepressant drug venlafaxine HCL, International Journal of Research in Pharmaceutical Sciences. 2018;9(4):1146-1153.

3. Patel H, Parmar S, Patel B. A comprehensive review on quality by design (QbD) in pharmaceuticals, Int J Pharm Sci Rev Res. 2013;21(1):223-236.

4. Nadpara NP, Thumar RV, Kolala VN, Patel PB. “Quality by design (QbD): A complete review, International Journal of Pharmaceutical Sciences Review and Research. 2012;17(2):20-28.

5. Sanjay B, Sarwar B, Babita G, Abbay A, Gyati S. Asthana, Bhopinder S. QbD-Oriented Development and Characterization of Effervescent Floating-Bioadhesive Tablets of Cefuroxime Axetil”, AAPS Pharm Sci Tech. 2016;17:1086–1099.

6. Ajinkya U, Sanjay K, Mangesh B. Design and optimization of sustained release matrix tablet of opipramol HCL by using quality by design approach”, Asian journal of pharmaceutical and Clinical Research. 2014;7:227-234.

7. Aleksandar Jc, Gaurav C, Francesco G. Designing the design of experiments (DOE) – An investigation on the influence of different factorial designs on the characterization of complex systems, Energy & buildings. 2011;250:111298.

8. Charles J Malemud, The role of the JAK/STAT signal pathway in rheumatoid arthritis, Ther Adv Musculoskelet Dis. 2018;10(5-6):117–127.

9. Manisha L, Rong W, Tracey F, et al Extended Release Once Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate Release Tofacitinib and Impact of Food, The Journal of Clinical Pharmacology. 2020;60(2):1-12.

10. Ruija X, Chenhui D, Qiang W, Keith S. et al. Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis, Int. Journal of Clinical Pharmacology and Therapeutics. 2019; 57(9):464–473.

11. Zhihong O’Brien, Mehran F Moghaddam. A Systematic Analysis of Physicochemical and ADME Properties of All Small Molecule Kinase Inhibitors Approved by US FDA from January 2001 to October 2015", Current Medicinal Chemistry. 2017;24(29):3159–3184.

12. Nitin T, Manish R, Jayesh P, Ali Rajabi-S. Application of Quality by Design (QbD) Principles in the Formulation of Hupromellose Hydrophilic Matrix Tablets, Pharma Times. 2014;46(08):20.

13. Usir S Younis, Ernest Vallorz, Kenneth J, Addison, Julie G, Ledford, Paul B Myrdal, Preformulation and Evaluation of Tofacitinib as a Therapeutic Treatment for Asthma, AAPS PharmSciTech. 2019;20(5): 167.

14. Chinmaya KS, Surepalli RMR, Muvvala S, HPMC a biomedical polymer in pharmaceutical dosage forms Journal of Chemical and Pharmaceutical Sciences. 2015;8:875-881.

15. Gurpreet A, Karan M, Inderbir S, Sandeep A, Vikas R. Formulation and evaluation of controlled release matrix mucoadhesive tablets of domperidone using Salvia plebeian gum, Journal of Advanced Pharmaceutical Technology & Research. 2011;2(3):163–169.

© 2021 Barik et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history: The peer review history for this paper can be accessed here: https://www.sdiarticle5.com/review-history/82842